• Opeolu Adeoye, Daniel Woo, Mary Haverbusch, Haiyang Tao, Padmini Sekar, Charles J Moomaw, Lori Shutter, Dawn Kleindorfer, Brett Kissela, Joseph Broderick, and Matthew L Flaherty.
• Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA. opeolu.adeoye@uc.edu
• Neurocrit Care. 2008 Jan 1; 9 (2): 237-41.

IntroductionNo proven treatments exist for intracerebral hemorrhage (ICH). Carefully selected patients may benefit from surgery, and an international multicenter trial is ongoing. We sought to determine how many patients in a population-based ICH cohort would have been eligible for surgery using the Surgical Trial in Intracerebral Hemorrhage II (STICH II) criteria.MethodsWe identified all patients aged > or =18 years residing in the five-county Greater Cincinnati region who were hospitalized with first-ever nontraumatic ICH in 2005. STICH II trial criteria were used to determine eligibility for treatment and reasons for exclusion.ResultsDuring 2005, 286 ICH patients were identified (103 lobar, 126 deep cerebral, 23 brainstem, 28 cerebellar, and 6 IVH). Non-lobar hemorrhages are not eligible for STICH II. Among patients with lobar hemorrhage, 22 had no exclusions. The most common (not mutually exclusive) reasons for exclusion were volume <10 cc or >100 cc (n = 46) and presence of IVH (n = 27). No significant age, gender or racial differences existed between eligible and ineligible patients with lobar ICH. Only one (4.5%) of the 22 STICH II eligible patients in our population had surgery, compared with eight of 81 (9.9%) ineligible lobar ICH patients (P = 0.43). Mortality at 180 days in STICH II eligible patients was 36% vs. 49% for ineligible lobar ICH patients (P = 0.19).ConclusionsIn this population-based ICH cohort, 7.7% (22 of 286) of ICH patients would have qualified for STICH II enrollment. Other treatment options need to be explored for most ICH patients.

18 keywords...

hide…